

BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

Officially Licensed Best of ASCO® India 2026 Conference
19th to 21st June 2026 | Jaipur Marriott Hotel

Organizing Chairperson: Prof. Dr. Hemant Malhotra & Scientific Chairperson: Dr. Purvish Parikh
Scientific Committee Co-Chairperson: Dr. Ajay Bapna
Organizing Committee Co-Chairpersons: Dr. Naresh Somani & Dr. Sandeep Jasuja
Program Director: Dr. Abhishek Charan

Day 1 | 19th June, 2026 | Friday

Main Conference

12:00 pm to 12:45 pm	Quiz Qualifying Round Quizmaster - Dr. Satyajeet Soni	
12:00 pm to 12:45 pm	Lunch	
12:45 pm to 1:25 pm	Academic Session 1 - GU Cancer Chairpersons: Dr. Ganesh K Bakshi & Dr. Sunit Lokwani	
12:45 - 12:50	LBA1: Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study	Dr. Hollis D'Souza
12:50 - 12:55	5001: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.	Dr. Ajay Yadav
12:55 - 1:00	5005: Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.	Dr. Bhavesh Pradeep Poladia
1:00 - 1:25	Panel Discussion Moderator: Dr. Vineet Talwar Panelists: Dr. Vinod Sharma, Dr. Tanmoy Mandal, Dr. Uma Dangi, Dr. Amit Joshi, Dr. TVSVGK Tilak, Dr. Hollis D'Souza, Dr. Mansi Sandip Shah, Dr. Jyoti Wadhwa & Dr. Anbarasan Sekar	
1:30 pm to 1:50 pm	Sponsored Symposium (Roche) Recent development in the management of intermediate HCC with atezolizumab plus Bevacizumab Speaker - Dr. Pulkat Nag	





BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

1:50 pm to 2:10 pm	Sponsored Symposium (NATCO) FGFR Inhibition Redefined: Clinical Impact of Erdafitinib Speaker: Dr. Amit Joshi	
2:10 pm to 2:30 pm	Sponsored Symposium (AstraZeneca) Optimising survival outcomes in HER2+ mBC Speaker - Dr. Bhuvan Chugh	
2:30 pm to 3:20 pm	Academic Session 2 - Breast Cancer 1 Chairperson: Dr. BK Smruti	
2:30 - 2:35	500: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.	Dr. Soumya Surath Panda
2:35 - 2:40	LBA503: Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.	Dr. Anbarasan Sekar
2:40 - 2:45	1004: Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.	Dr. Seema Gulia
2:45 - 2:50	1005: Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.	Dr. Mansi Sandip Shah
2:50 - 3:20	Panel Discussion Moderators: Dr. Bhuvan Chugh & Dr. MV Chandrakanth Panelists: Dr. Charu Bahl, Dr. Mohit Sharma, Dr. Jitendra Kumar Pehalajani, Prof (Dr.) Shishir Shetty, Dr. Indoo Ammbulkar, Dr. Rima Pathak, Dr. Barnini Ghosh, Dr. Priti Agarwal & Dr. Sudhir Palsaniya	
3:20 pm to 3:30 pm	Sponsored Symposium (Roche) Continuum of Care in HER 2+ BC Speaker - Dr. Mansi Sandip Shah	
3:30 pm to 3:45 pm	Sponsored Symposium (Zydus) Present and Future Landscape of HER2 +ve Breast cancer management Speaker - Dr. Rishabh Jain	







BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR


3:50 pm to 4:20 pm	Sponsored Symposium (Eli Lilly) Panel Discussion on EBC Moderator - Dr. M Vamshi Krishna Panelists - Dr. Poonam Patil & Dr. MV Chandrakanth	
4:20 pm to 4:40 pm	Sponsored Symposium (MSD) UNLOCKING the Immune Response_Role of Immunotherapy in Early TNBC A Multidisciplinary Approach Speaker: Dr. Jyoti Wadhwa	
4:40 pm to 5:20 pm	Academic Session 3 - Breast Cancer 2 Chairpersons: Dr. Rohit Swami, Dr. Lalit Sharma & Dr. Satyanker Gupta	
4:40 - 4:45	LBA1006: Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.	Dr. Tara Chand Gupta
4:45 - 4:50	LBA1007: First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the Phase III SERENA-6 trial.	Dr. Ankur Punia
4:50 - 4:55	LBA1000: Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.	Dr. Sunit Lokwani
4:55 - 5:20	Panel Discussion Moderator: Dr. Tarini Prasad Sahoo Panelists: Dr. Nikhil Mehta, Dr. Sushil Mandhaniya, Dr. Tanmoy Mandal, Dr. Bhavesh Pradeep Poladia, Dr. Akshay Shivchhand, Dr. Amit Verma, Dr. Kushal Gupta, Dr. Rakesh Roy & Dr. Dharmpal Jakhar	
5:25 pm to 5:40 pm	Sponsored Symposium (Bayer) Shaping the future of mHSPC management with ARANOTE Launch Speaker - Dr. Pulkit Nag	
5:40 pm to 6:25 pm	Artificial Intelligence - what oncologists must know today	Dr. Purvish Parikh
6:25 pm to 7:05 pm	Academic Session 4 - Gynecologic Cancer Chairpersons: Dr. Poonam Patil & Dr. Apoorva Tak	



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

6:25 - 6:30	5505: CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.	Dr. Rashmi Bansal
6:30 - 6:35	5506: A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).	Dr. Rejiv Rajendranath
6:35 - 6:40	5517: Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.	Dr. Mukesh Jandu
6:40 - 7:05	Panel Discussion Moderator: Dr. Naresh Somani Panelists: Dr. Pawan Agarwal, Dr. Prashant Pandey, Dr. Sajna Choudhary, Dr. Amita Maheshwari, Dr. Neelam Singh, Dr. Rejiv Rajendranath, Dr. Satinder Kaur & Dr. Apoorva Tak	
7:10 pm to 7:30 pm	Sponsored Symposium (GSK) Ruby Trial: Survival Impact of Jemperli in 1L EC Speaker - Dr. Aseem Kumar Samar	
7:30 pm to 7:50 pm	Sponsored Symposium (MSD) The Evolving Role of Immunotherapy in the Locally Advanced Cervical Cancer Speaker: Dr. Ankit Agarwal	
7:50 pm to 8:30 pm	Academic Session 5 - GU Cancer Chairpersons: Prof. Dr. Hemant Malhotra, Dr. Ananya Pareek & Dr. Rishabh Jain	
7:50 - 7:55	5030: Regional trends in testicular cancer burden among adolescents and young adults (15–39 years), 1990–2023: A Global Burden of Disease analysis.	Dr. Subhash Bairwa
7:55 - 8:00	4504: Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.	Dr. Satyajeet Soni
8:00 - 8:05	108: An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).	Dr. Deepak Agrawal
8:05 - 8:30	Panel Discussion Moderator: Dr. M Vamshi Krishna	




BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

	Panelists: Dr. Lalit Mohan Sharma, Dr. Prashant Kumbhaj, Dr. Vinod Sharma, Dr. Tanmoy Mandal, Dr. Subhash Bairwa, Dr. Satyajeet Soni, Dr. Deepak Agrawal & Dr. Akshay Shivchhand	
8:30 pm onwards	Dinner	
Day 2 20 th June, 2026 Saturday		
Main Conference		
9:00 am to 9:40 am	Academic Session 6 - GI Cancer 1 (Non-Colorectal) Chairpersons: Dr. Girish Phadke, Dr. Nidhi Patni & Dr. Sanjeev Patni	
9:00 - 9:05	LBA4000: Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with embolization-eligible unresectable hepatocellular carcinoma (HCC).	Dr. Asma Pathan
9:05 - 9:10	LBA5: Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study.	Dr. Indranil Ghosh
9:10 - 9:15	4009: Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.	Dr. Prabhat Bhargava
9:15 - 9:40	Panel Discussion Moderator: Prof Anant Ramaswamy Panelists: Dr. Rohan Jacob Verghese, Dr. Neha Rawat, Dr. Kumar Saurabh, Dr. Satyanker Gupta, Dr. Pavan Raghava Reddy K, Dr. Navya Manasa V, Dr. Kapil Raut, Dr. Aparna Dhar, Dr. Renu Mishra & Dr. Somashekhar S P	
9:45 am to 10:05 am	Sponsored Symposium (AstraZeneca) Transforming Patient outcome with Stride Speaker - Dr. Vineet Talwar	
10:05 am to 10:20 am	Sponsored Symposium (Advance Medilinks) Clinical Utility of Signatera Speaker - Dr. Anant Ramaswamy	
10:25 am to 11:05 am	Academic Session 7 - GI Cancer 2 (Colorectal) Chairpersons: Dr. Somashekhar S P, Dr. Suresh Singh & Prof. Dr Raj Govind Sharma	







BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

10:25 - 10:30	102: Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.	Dr. Mukesh Kumar Chaudhary
10:30 - 10:35	LBA3503: BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).	Dr. Deepak Agrawal
10:35 - 10:40	LBA3517: AZUR-1: A phase II study of neoadjuvant dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer.	Dr. Saphalta Baghmar
10:40 - 11:05	Panel Discussion Moderator: Dr. Randeep Singh Panelists: Dr. Saphalta Baghmar, Dr. Ravikumar Wategaonkar, Dr. Mukesh Kumar Chaudhary, Dr. Sandeep Batra, Dr. Prasad Narayanan, Dr. Ajay Choudhary, Dr. Nimesh Agarwal & Dr. Bharath Rangarajan	
11:05 am to 11:20 am	Sponsored Symposium (LalPathLabs) Pancreatic Cancer: From Enigma to KRAS in the Era of Precision Medicine Speaker - Dr. Vamshi Krishna Thamtam	
11:25 am to 11:45 am	Advancing precision medicine in mIDH Glioma management - INDIGO Trial Speaker - Dr. Ankit Agarwal	
11:50 am to 12:05 pm	Sponsored Symposium (Pfizer) Role of BCMA bispecifics in RRMM in India Speaker: Dr. Hemant Malhotra	
12:10 pm to 12:50 pm	Academic Session 8 - Hemat - Myeloma Chairpersons: Dr. Prakash Singh Shekhawat, Dr. Vishnu Sharma & Dr. Naveen Gupta	
12:10 - 12:15	7501: Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.	Dr. Prashant Mehta
12:15 - 12:20	LBA7506: Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.	Dr. PK Jayachandran
12:20 - 12:25	7507: MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator's choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and	Dr. Bhausahab Bagal



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR


	dexamethasone (PvD/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).	
12:25 - 12:50	Panel Discussion Moderator: Prof. Dr. Hemant Malhotra Panelists: Dr. Vishnu Sharma, Dr. Suhas Aagre, Dr. Priyanka Srivastava, Dr. Rachana Chennamaneni, Dr. Aditi Mittal, Dr. Ashish Verma, Dr. Kunal Jain, Dr. Ranjeet Kashnia, Dr. Abhishek Sharma & Dr. Umesh Khandelwal	
1:00 pm to 1:50 pm	Lunch	
1:50 pm to 2:15 pm	Academic Session 9 - Hemat - NHL and Myelofibrosis Chairpersons: Dr. Rajesh Pasricha & Dr. PK Jayachandran	
1:50 - 1:55	LBA6500: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial	Dr. Anant Gokarn
1:55 - 2:00	LBA7000: frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).	Dr. Priyanka Srivastava
2:00 - 2:15	Panel Discussion Moderator: Dr. Prakash Singh Shekhawat Panelists: Dr. PK Jayachandran, Dr. Babita Kumari Drolia, Dr. Rakesh Roy, Dr. R K Spartacus, Dr. Hemant Dadhich, Dr. Naveen Gupta, Dr. Anant Gokarn & Dr. Vishnu Sharma	
2:15 pm to 2:35 pm	Sponsored Symposium (Astellas) Redefining outcomes in Bladder Cancer: Evolution of PADCEV in 1L LA/mUC Speaker - Dr. Vineet Talwar	
2:35 pm to 2:45 pm	Sponsored Symposium (ImmunoAct) Leading Change Through Evidence: Real-World CAR-T Outcomes in Lymphoma Speaker - Dr. Prashant Mehta	
2:45 pm to 2:55 pm	Sponsored Symposium (ImmunoAct) Panel Discussion: NEXCAR19 CAR-T Therapy in Lymphoma: Addressing Clinical Dilemmas Through Case-Based Expert Discussion	
2:55 pm to 3:15 pm	Sponsored Symposium (Abbvie) Venclexta voyage transforming the treatment paradigm in CLL Speaker - Dr. Nataraj KS	
3:15 pm to 4:05 pm	Academic Session 10 - ImmunoOncology 1 Chairpersons - Dr. Jatin Sarin, Dr. Sajna Choudhary & Dr. Priyanka Choudhary	



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR



3:15 - 3:20	2502: DART (NCI/SWOG S1609): Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.	Dr. Rajeev Vijayakumar
3:20 - 3:25	3143: Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.	Dr. Reshma Puranik
3:25 - 3:30	11000: The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.	Dr. Pranjil Mandloi
3:30 - 3:35	7008: Mediterranean CD19 genetic variations and potential influence on CAR T-cell therapy efficacy: Implications for population-tailored immunotherapy.	Dr. Anshul Agarwal
3:35 - 4:05	Panel Discussion Moderator: Dr. Bharath Rangarajan Panelists: Dr. Rohan Jacob Verghese, Dr. Aditya Sarin, Dr. Santosh Kumar Swain, Dr. Ananya Pareek, Dr. Ankit Agarwal, Dr. Rohit Swami, Dr. Roshni Bhagwat Pande, Dr. Prabhat Ganju & Dr. Mukesh Jandu	
4:05 pm to 4:30 pm	Sponsored Symposium (Roche) Advancing Immunotherapy in Lung Cancer: Tecentriq Mono therapy and the innovation of Tecentriq SC Moderator - Dr Bhavesh Parekh Chairperson - Dr. Bharat J. Parikh Panelists: Dr Ankit Agarwal, Dr. Deepak Gupta, Dr. Priti Agarwal, Dr. MV Chandrakanth & Dr. Ajay Yadav	
4:30 pm to 5:00 pm	Sponsored Symposium (Pfizer) Redefining Long term ALK+ NSCLC Care and Survivorship Chairperson - Dr. Ajay Bapna Moderator - Dr. Amish Vora Panelists - Dr. Deepak Gupta, Dr. Aseem Samar, Dr. Surendra Beniwal, Dr. Sandeep Jasuja, Dr. Tara Chand Gupta, Dr. Randeep Singh & Dr. Ishu Gupta	
5:00 pm to 5:10 pm	Sponsored Symposium (Intas) Next Gen IO - what's different Speaker: Dr. Ishu Gupta	
5:10 pm to 5:30 pm	Sponsored Symposium (Intas) Reinventing a Better Wheel in Lung Cancer with Serplulimab	



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR


	Moderator: Dr. Tarini Prasad Sahoo Panelists - Dr. Naresh Somani, Dr. Anbarasan Sekar, Dr. M Vamshi Krishna, Dr. Bharat Bhosale, Dr. Surendra Beniwal, Dr. Abhishek Sharma & Dr. Mukesh Rulaniya	
5:30 pm to 6:20 pm	Academic Session 11 - Lung Cancer 1 Chairpersons: Dr. PK Jayachandran, Prof. Dr. Hemant Malhotra & Dr. Bharat J. Parikh	
5:30 - 5:35	LBA3: Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial	Dr. Barnini Ghosh
5:35 - 5:40	8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).	Dr. Kritthivasan Venkatakrishnan
5:40 - 5:45	8004: Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.	Dr. Prabhat Ganju
5:45 - 5:50	8006: Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.	Dr. Aditya Sarin
5:50 - 6:20	Panel Discussion Moderator: Dr. Prasad Narayanan Panelists: Dr. Rajesh Pasricha, Dr. Ravikumar Wategaonkar, Dr. Sushil Mandhaniya, Dr. Pranji Mandloi, Dr. Dharmpal Jakhar, Dr. Ashish M Vaidya, Dr. Rashmi Bansal, Dr. Darshana Rane, Dr. Suruchi Aggarwal & Dr. Rohit Rebello	
6:20 pm to 6:30 pm	Sponsored Symposium (Roche) 7 year Survival in ES - SCLC with Atezolizumab Speaker - Dr Archit Joshi	
6:30 pm to 6:40 pm	Sponsored Symposium (Datar Genetics) CellDx: India's First FDA-Cleared CGP Platform — Empowering Oncologists with Globally Validated Precision Oncology Speaker: Dr. Silambarasan Maskomani	
6:45 pm to 7:00 pm	Sponsored Symposium (Zydus) Role of Nivolumab in SCHN Carcinoma: Innovation to Impact Speaker - Dr. Kaushal Kalra	
7:00 pm to 7:50 pm	Academic Session 12 - ImmunoOncology 2 Chairpersons: Dr. B. K. Mishra & Dr. Jatin Sarin	



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

7:00 - 7:05	LBA6007: Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.	Dr. Savinay Ramji Dighiya
7:05 - 7:10	6002: Metronomic adjuvant chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment (MACE postop): A phase III randomized controlled trial.	Dr. Jerin J Ovett
7:10 - 7:15	LBA9505: Updated Outcomes from STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial: ECOG-ACRIN EA6174	Dr. Bharat Patodiya
7:15 - 7:20	9518: A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGRYTE clinical trial.	Dr. Aditya Sarin
7:20 - 7:50	Panel Discussion Moderators: Dr. Kumar Prabhash & Dr. Rajeev Vijayakumar Panelists: Dr. Archit Joshi, Dr. Mukesh Rulaniya, Dr. Jaishree Goyal, Dr. Savinay Ramji Dighiya, Dr. Jerin J Ovett, Dr. Anushree Chaturvedi, Dr. Kritika Mehrotra & Dr. Priyanka Choudhary	
7:50 pm to 8:30 pm	Inauguration	
8:30 pm onwards	Dinner	
Day 2 20 th June, 2026 Saturday		
Board Room		
3:00 pm to 4:00 pm	Intas Advisory Board	
4:15 pm to 5:30 pm	Servier Advisory Board GLIOSIGHT - Understanding clinical practice patterns in glioma patients	
8:30 pm to 9:30 pm	Closed Door Meeting - Steering the Future of Medical Oncology Round Table Discussion Session Coordinators - Dr. Purvish Parikh & Dr. Ajay Bapna Experts - Dr. Randeep Singh, Dr. Kumar Prabhash, Dr. Naresh Somani, Dr. Kaushal Kalra, Dr. Sandeep Jasuja, Dr. Nikhil Suresh Ghadyalpatil, Prof. Dr. Hemant Malhotra, Dr. Prashant Mehta & Dr. Prasad Narayanan	



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

Day 3 | 21st June, 2026 | Sunday

Main Conference

8:15 am to 9:00 am

Quiz Finals

Quizmaster - Dr. Satyajeet Soni

9:00 am to 9:40 am

Academic Session 13 - Lung Cancer 2

Chairpersons: Dr. Sandeep Jasuja, Dr. Girdhar Singh Bhati & Dr. Deepak Kumar Uppal

9:00 - 9:05

LBA1510: Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial

Dr. Stalin Chowdary Bala

9:05 - 9:10

LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).

Dr. Krupa Shankar S

9:10 - 9:15

8506: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.

Dr. Bharat Bhosale

9:15 - 9:40

Panel Discussion

Moderator: Dr. Nikhil Suresh Ghadyalpatil

Panelists: Dr. Aditya Sarin, Dr. Sachin Jain, Dr. Kritthivasan Venkatakrishnan, Dr. Abhijit Sarkar, Dr. Vamsivihari, Dr. Mansi Sharma, Dr. Aseem Samar, Dr. Karan Sood & Dr. Vinod Sharma

9:45 am to 10:00 am

Sponsored Symposium (Eli Lilly)

Management of RET altered lung cancer

Speaker - Dr. Pulkit Nag

10:05 am to 10:25 am

Sponsored Symposium (Merck)

Maintain to extend - right approach to maximize overall survival in mUC

Speaker - Dr. Jitendra Kumar Pehalajani

10:25 am to 11:05 am


Academic Session 14 - Sarcoma

Chairpersons: Dr. Bharat J. Parikh & Prof. Dr. Hemant Malhotra

10:25 - 10:30

LBA2: SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.



Dr. Anjana Sainani



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR



10:30 - 10:35	11500: Primary results of the phase 3 peak study of bezucastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).	Dr. Deepak Kumar Uppal
10:35 - 10:40	11506: RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.	Dr. Ashay Karpe
10:40 - 11:05	Panel Discussion Moderator: Dr. Atul Sharma Panelists: Dr. Jatin Choudhary, Dr. Pawan Kumar, Dr. Krupa Shankar S, Dr. Ram Krishna, Dr. Surendra Beniwal, Dr. Sumit Goyal, Dr. Jitendra Kumar Pehalajani, Dr. Priya P Nayak & Dr. Koushik Chatterjee	
11:10 am to 12:00 pm	Academic Session 15 - Head & Neck Cancer Chairpersons: Dr. Palkonda Vijay Anand Reddy, Dr. Anil K Dcruz & Dr. Anushree Loyal	
11:10 - 11:15	6000: Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).	Dr. Peush Bajpai
11:15 - 11:20	6004: Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.	Dr. Pulkit Nag
11:20 - 11:25	6008: Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.	Dr. Kshitij Domadia
11:25 - 11:30	6011: Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase II MYTHOS trial.	Dr. Stalin Chowdary Bala
11:30 - 12:00	Panel Discussion Moderators: Dr. Kumar Prabhash & Dr. Krupa Shankar S Panelists: Dr. Kampra Gupta, Dr. Kapil Dev, Dr. Meetu Jain, Dr. Gaurav Goel, Dr. Trinanjan Basu, Dr. Divesh Goyal, Dr. Sandeep Bhaskar, Dr. Pulkit Nag, Dr. Bhavesh Parekh & Dr. Rishabh Jain	
12:00 pm to 12:30 pm	Sponsored Symposium (MSD) From Metastatic to Curative Intent: Integrating Immunotherapy in Early-Stage Head & Neck Cancer Speaker: Dr. Shyam Aggarwal	



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

12:40 pm to 1:30 pm	Academic Session 16 - Oncology Beyond the Obvious (OBTO) Session Directors: Dr. Purvish Parikh & Dr. Amish Vora	
12:40 - 12:45	LBA100: NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.	Dr. Aseem Samar
12:45 - 12:50	10503: Effect of type and location of BRCA2 deleterious variant on prognosis and survival in metastatic prostate cancer: A longitudinal, international, cohort study from hormone-sensitive to castration-resistant settings.	Dr. Bharat Patodiya
12:50 - 12:55	10515: Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.	Dr. Abhishek Sharma
12:55 - 1:00	11005: Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.	Dr. Manoj U Mahajan
1:00 - 1:30	Panel Discussion Moderator: Dr. Shyam Aggarwal Panelists: Dr. Bharat Patodiya, Dr. Manoj U Mahajan, Dr. Anjana Sainani, Dr. Abhishek Sharma, Dr. Kritika Mehrotra, Dr. Divesh Goyal, Dr. Peush Bajpai, Dr. Reetu Jain & Dr. Jatin Choudhary	
1:30 pm to 2:30 pm	Academic Session 17 - Supportive Care and Public Health Chairpersons: Dr. Nipun Lamba, Dr. Anjum Khan & Dr. Upendra Sharma	
1:30 - 1:35	12000: Dexamethasone reduction or omission with NEPA and olanzapine for HEC: A phase III trial.	Dr. Abhishek Sharma
1:35 - 1:40	LBA12003: Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results.	Dr. Annu Rajpurohit
1:40 - 1:45	12004: YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors.	Dr. Karan Sood
1:45 - 1:50	12010: Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.	Dr. Manish Gautam
1:50 - 1:55	LBA12008: SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized controlled trial.	Dr. Kripa Bajaj



BEST OF ASCO® INDIA 2026

19TH TO 21ST JUNE, 2026 | JAIPUR

1:55 - 2:00	1508: Essential but unaffordable: Real-world costs of WHO essential cancer medicines in a low-income setting.	Dr. Kripa Bajaj
2:00 - 2:30	Panel Discussion Moderators: Dr. Bharat Bhosale & Dr. Amish Vora Panelists: Dr. Tarun Kumar Jain, Dr. Manish Gautam, Dr. Karan Sood, Dr. Kripa Bajaj, Dr. Shyam Aggarwal, Dr. Bhavesh Parekh, Dr. Reetu Jain & Dr. Annu Rajpurohit	
2:30 pm onwards	Lunch	